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Guyana is one of four countries in the Latin American Region where lymphatic filariasis (LF)
remains endemic. In preparation for the introduction of a new triple drug therapy regimen
(ivermectin, diethylcarbamazine, and albendazole (IDA)) in 2019, an acceptability study
was embedded within sentinel site mapping in four regions to assess mass drug administra-
tion (MDA) coverage and compliance, acceptability, and perceptions about treatment and
disease. The results from this survey would inform the rollout of IDA in Guyana in 2019.
Methods
Data collection for the study occurred in August 2019, using a validated questionnaire
administered by trained enumerators. Across all regions, a total of 1,248 participants were
sampled by the Filarial Mapping team. Four-hundred and fifty-one participants aged over 18
years were randomly selected for participation in an expanded acceptability questionnaire.
All data were captured in Secure Data Kit (SDK).
Results
Acceptability was measured using a mean acceptability score. Unadjusted mean scores
ranged from 24.6 to 29.3, with 22.5 as the threshold of acceptability. Regional variation
occurred across many indicators of interest: self-rated understanding about LF, mecha-
nisms of LF transmission, LF drug safety and history of treatment during MDA. Region IV
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(Georgetown) recorded higher knowledge about LF, but lower compliance and acceptability.
Number of pills was not perceived as a concern.
Conclusion
Acceptability of MDA was good across all four regions under study. Results from this study
set a baseline level for key indicators and acceptability, from which the acceptability of IDA
can be measured. Regional variations across indicators suggest that localized approaches
should be considered for social mobilization and MDA delivery to capture these contextual
differences.
Author summary
Guyana is one of four countries in the Latin American Region where lymphatic filariasis
(LF) remains endemic in the community. In preparation for a new treatment regimen
using three drugs instead of two, the research team assessed how community members in
four regions of Guyana accepted the current two-drug treatment offered for LF during
mass drug administration. Results from 390 participants showed that people generally
accepted the treatment; however regional variation was high. Recommendations were
made to the government program to inform the use of the new three-drug treatment regi-
men, including the need for localized approaches.
Introduction
Lymphatic filariasis (LF), a neglected tropical disease (NTD), is a parasitic infection caused by
the filarial nematodes Wuchereria bancrofti, Brugia malayi, and Brugia timori [1]. These para-
sites are transmitted by mosquito and mature into adult worms within the human lymphatic
system following infection, causing excessive and painful swelling of the limbs, the genitals
and, occasionally in women, the breasts [1–3]. Symptomatic LF can be debilitating, leading
patients to suffer negative physical, mental, social and economic outcomes [4–6]. In 2019, LF
was endemic in 72 countries and considered a public health threat in 50, representing a total
at-risk population of approximately 858.3 million people still requiring preventive chemother-
apy [7]. This represents a decrease of 43% from the total population identified as being at-risk
for infection by the Global Programme for the Elimination of Lymphatic Filariasis (GPELF)
since 2010 [7].
Efforts undertaken by the GPELF to eliminate LF as a public health problem are based on
the strategies of mass drug administration (MDA) of preventive chemotherapy to break trans-
mission of LF, and morbidity management and disability prevention (MMDP) to address LF-
associated morbidities in infected patients [8–10]. Since 2000, the GPELF, national ministries
of health, the World Health Organization (WHO) and other partners have worked together to
implement these strategies with the goal of achieving the target of global elimination of LF as a
public health problem [8,11,12]. Elimination is based on preventing infection through MDA,
whereby all eligible community members living within an endemic area, regardless of infection
status, are given an annual regimen of antifilarial treatments (diethylcarbamazine (DEC) plus
albendazole (DA); or ivermectin plus albendazole (IA) in sub-Saharan African communities
co-endemic with onchocerciasis) [10]. Annual treatment with DA or IA for at least five years
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has been shown to drastically reduce human reservoirs of W. bancrofti, B. malayi, and B.
timori, preventing these parasites from being transmitted by mosquito vectors [10].
Guyana is one of four countries in the Latin America and Caribbean (LAC) Region known
to be endemic with LF; with the others being Brazil, the Dominican Republic, and Haiti [13].
Risk-mapping of the environmental suitability for LF transmission in Central and South
America has indicated that the physical environment in this region is conducive for wide-
spread active transmission of W. bancrofti [14]. However, in LAC countries such as Guyana,
transmission of the disease-causing parasite occurs in isolated foci [14]. One possible explana-
tion is that transmission in the LAC region is highly influenced by various historical socioeco-
nomic and sociodemographic risk factors, rather than environmental factors alone [14]. Such
risk factors include poverty, living environment (urban slums and poor rural communities),
age, gender, and ethnicity [5,14,15]. In addition, improvements in vector control, and water,
sanitation, and hygiene (WASH) practices have limited widespread transmission of LF [14].
While active transmission is thought to be largely constrained to urban and poor socioeco-
nomic environments, in 1995 approximately 81.3% of Guyana’s 799,000 people were estimated
to be at-risk of LF infection [16]. Metrics provided by WHO in 2018 revised the total at-risk
population in Guyana requiring MDA to 719,312 [17]. Nationwide mapping of LF infection
among school children conducted in 2001 estimated approximately 9.3% of the population
was positive for antigenemia, with variation across administrative regions [18]. The mapping
revealed higher LF prevalence in six of Guyana’s ten administrative regions, especially in
urban centers such as the cities of Georgetown, New Amsterdam and Linden [18]. The six
regions with the highest prevalence of LF are also Guyana’s most populated [18].
To address LF endemicity in Guyana, the Guyanese Ministry of Health established the
Lymphatic Filariasis Elimination Program. The program involved integrating treatments for
lymphedema into primary healthcare services and a two-phase prevention effort [18]. Phase
one of this prevention effort ran from 2003–2007 and involved social mobilization, and the
promotion and distribution of DEC-fortified salt rather than antifilarial tablets, as the limited
availability of health staff across various regions interfered with the implementation of a tablet-
based MDA [18,19]. Phase one achieved much early success. However, due to disruptions in
production and other technical problems, prevention efforts shifted to MDA with DA, signify-
ing the beginning of phase two in 2008 [18,19]. While the program has achieved effective cov-
erage in several regions, it has had variable success in others. As of 2017, approximately 60.9%
of the population requiring preventive chemotherapy received it from the LF program [20]. In
2019, the LF program in Guyana adopted the use of the triple drug therapy for LF [ivermectin,
DEC, and albendazole (IDA)] to accelerate its LF elimination program [21]. With the intro-
duction of IDA, the LF program in Guyana also saw an opportunity to evaluate past coverage
and compliance and revise social mobilization strategies prior to the launch of the new treat-
ment regimen.
Evaluation of past coverage and compliance with MDA in Guyana was based on known fac-
tors influencing participation from global research [22]. In addition to coverage and compli-
ance, increasingly individuals’ perceptions of the acceptability of interventions for LF
elimination (e.g. MDA) are being investigated as an important consideration for their success
[23]. Treatment acceptability is the extent to which people consider an intervention to be
appropriate, based on their cognitive or emotional responses to that intervention [24]. Ele-
ments of a treatment that are thought to contribute to individuals’ evaluations of its acceptabil-
ity include the treatment’s effectiveness, importance, intrusiveness, characteristics, side effects,
and whether it aligns with the evaluator’s values or beliefs [24–31]. In addition, an individual’s
sociodemographic or socioeconomic characteristics and the societal norms of the community
to which they belong can influence their perceptions of the treatment’s acceptability [24–32].
PLOS NEGLECTED TROPICAL DISEASES Assessing community acceptability for MDA in Guyana
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009596 September 20, 2021 3 / 27
If individuals or communities deem MDA to be unacceptable, they are unlikely to be moti-
vated to participate in the intervention.
The purpose of this study was to assess Guyanese community members’ perceptions of the
acceptability of MDA in four administrative regions through use of a community-based treat-
ment acceptability assessment survey [23], embedded within a larger sentinel site survey.
While coverage and compliance data are critical indicators of the program’s success, they may
not adequately capture individuals’ attitudes towards the intervention or their motivations for
participating (or not participating) in MDA. Furthermore, in regions or communities where
coverage and compliance rates are high, the binary nature of these outcome variables often do
not provide the granularity necessary for identifying reasons of non-compliance. The use of an
acceptability measure allows for a more nuanced understanding of individuals’ attitudes
towards MDA and can provide useful information about what aspects of the intervention
encourage or deter individuals from accepting treatment. The acceptability study was used to
inform the rollout of the 2019 MDA with IDA and provide recommendations to the LF pro-
gram in Guyana to maximize success.
Methods
Ethics statement
Ethics was approved through the Ministry of Health, Guyana (IRB #599/2019) and through
the Pan American Health Organization (PAHOERC #0090.01). Formal written consent was
obtained for all participants.
Study design & setting
A cross-sectional survey of four regions in Guyana was conducted as part of a Filarial Re-Map-
ping Project by the Guyanese Ministry of Health as recommended by GPELF and WHO to
monitor filarial transmission in high-risk areas and to assess the baseline prevalence of LF in
four targeted regions before the 2019 MDA using IDA (see Fig 1). Sampling of the mapping
census was conducted according to WHO guidance on the monitoring and epidemiological
assessment of MDA [33]. Sentinel sites were chosen from areas within the four regions using
the following criteria: 1) populations of at least 500 people, targeting samples of at least 300
individuals; 2) where a high level of transmission was known to occur, or where difficulty in
achieving high drug coverage was anticipated; and 3) that have a stable population unlikely to
be affected by migration and that is similar in demographic characteristics to the implementa-
tion unit as a whole. Households were selected within the sentinel sites using Expanded Pro-
gram on Immunization recommended methods [34].
To create a similar baseline characteristic of population acceptability related to MDA, an
acceptability component was added to a random subsample of those included in the survey. A
sample of 400 individuals across all regions was targeted in accordance with established meth-
ods for exploratory studies [35].
Study population, participants & sampling
Data collection for the study occurred between the 16th and 31st of August 2019, with one sam-
pling team responsible for each study region. An outline of the sampling frame and further
inclusions and exclusion for subgroup analyses is detailed in Fig 2. Across all regions, a total of
1,248 participants were sampled by the Filarial Mapping team. Of these, one participant over
18 years in each household was selected to receive an expanded acceptability questionnaire
(n = 451) based on a previously validated tool [23]. Selection was determined by Random
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Number Generator [36] from among household members over 18 years of age who were pres-
ent at the time of the survey. All data were captured on smart phones using the Secure Data
Kit platform (Atlanta, GA, USA).
Three subsets of this dataset were used for analyses included in this paper. Our primary
analysis dataset of 390 participants included those selected for the expanded acceptability ques-
tionnaire who responded to all our covariates of interest, and to at least five out of nine accept-
ability scoring questions [23]. Participants with four or fewer missing acceptability scoring
questions had minimum values imputed for those questions as a conservative measure. No
other variables were imputed.
Due to an unexplained high number of missing responses to key analysis variables in one of
our study regions (Region X), a sensitivity dataset of 333 participants was created which
excluded the remaining data in that region. Identical models were created for both the stan-
dard and the sensitivity dataset to assess whether the missing data were biased in a meaningful
way that could impact the analyses.
A third subset of 298 participants was created to explore the attitudes of those who partici-
pated in the 2018 MDA of DEC and albendazole. This dataset included only those that self-
reported as having swallowed all the pills provided to them during the 2018 MDA.
Statistical analyses
Acceptability of DA was measured through a composite acceptability score which summed the
values of nine acceptability indicators that were each scored across a four-point scale [23]. The
possible range of acceptability scores were from 9–36, with 22.5 considered as the threshold of
acceptability. The acceptability measure was derived from the Intervention Rating Profile tool
[25] and has been described in more detail in a similar study in five countries [23]. The accept-
ability score was used as the primary outcome for analysis. A secondary analysis of variables
previously shown to be implicated in treatment acceptability, such as knowledge levels,
Fig 1. Description of study regions. Map content was produced with Esri ArcGIS software using data provided by Natural Earth (2018). [digital geospatial
data]. Available online: https://www.naturalearthdata.com/ [17/08/2021].
https://doi.org/10.1371/journal.pntd.0009596.g001
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perceptions of the disease, and perceptions of the treatment, was conducted using Stata 14.
Chi-square tests or Fisher’s exact tests were used where appropriate to compare these key vari-
ables across regions, sex, and previous compliance with treatment.
Given the importance of region as a covariate in the main study model, post-hoc individual
analyses were conducted by region to determine if specific differences in factors associated
with DA acceptability could be identified by region, to further target future MDA efforts. Due
to the small sample size in the region-specific models (n = 111, 106, 116, and 57 for Regions
III, IV, V, and X respectively), these should only be used to highlight areas for future research.
Model building
Modeling analyses were conducted in SAS v9.4 using PROC GENMOD (SAS, 2012). Relevant
covariates were selected based on prior analyses conducted by the research team in other
Fig 2. Acceptability study sampling frame and subset criteria.
https://doi.org/10.1371/journal.pntd.0009596.g002
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settings. The Primary, Sensitivity, Compliance, and Regional models were all computed as
standard linear regressions using the identity link function with the composite acceptability
score as the response variable. The systematic non-compliance model was defined as a logistic
regression with self-reported never/ever been treated in an MDA as the response variable. The
term “systematic non-compliance” is used to describe individuals who self-reported that they
had never been treated for LF during past rounds of MDA. Each of these models followed the
same model building process: 1) univariable models were computed for each covariate of
interest; 2) a full model was created using all covariates with significant responses (p< 0.05) in
the univariable model, in addition to any variables that were believed to be possible confound-
ers; and 3) covariates were removed from the model iteratively by increasing the level of signif-
icance until only significant covariates remained, unless doing so would cause a reduction in
model fit as determined by Akaike information criterion (corrected) (AICc). AICc is a mea-
sure of model fit which controls maximum likelihood for the number of parameters included
to prevent model overfitting, even in small samples [37].
Results
Sample population characteristics
A total of 390 surveys were included in the principal analyses. The sample data and regional
breakdown are shown in Table 1. The response sample was heavily skewed towards females
(72.8%). Similar sex ratios were observed across all four regions. The mean age of the sample
population was 43.4 years (range 18–89 years). Most of the study sample (64.6%) had attained
a secondary school education or greater, while only seven respondents indicated they had
received no formal education. One third of survey participants elected to report and elaborate
on their primary source of income using the “other” option. However, 22.3% of study partici-
pants classified their primary source of income as “private employment.” Agricultural activi-
ties, which includes fishing and farming, made up 17.2% of responses, largely driven by
Region V which predominately reported this category. Mean acceptability scores ranged from
24.6 in Region III to 29.3 in Region V. All four regions were above the threshold of acceptabil-
ity (a score of 22.5).
Predictors of acceptability in the primary study population
Multivariable analysis (Table 2) indicated that region was an important predictor of acceptabil-
ity, with Regions IV, V, and X having higher acceptability scores than those in Region III
(1.22; p = 0.0038, 3.95; p< 0.0001, and 1.40; p = 0.0052 points higher, respectively). Individu-
als who had knowledge that worms were involved in the transmission pathway for LF had a
mean acceptability score 1.39 points higher (p = 0.0070) than their counterparts who did not.
Those who indicated that mosquitoes were involved in transmission were less accepting, scor-
ing 2.32 (p = 0.0191) points lower, as were those who indicated other options (-3.19;
p = 0.0081), or did not know (-2.30; p = 0.0277). Opinions on the existence of asymptomatic
LF were associated with higher acceptability scores, whether the respondent indicated that it
did (0.87; p = 0.0467) or did not (1.25; p = 0.0217) exist, compared with those who responded
maybe (0.01; p = 0.9830), were unsure or didn’t know (referent). Individuals who responded
with “neutral” to their opinion that MDA is important for community health had higher
acceptability (3.03; p =< 0.0001) than those who did not know if MDA was important. Indi-
viduals who understood that you should take LF pills even if you are not sick had mean accept-
ability scores of 2.94 (p = 0.0003) higher over those who did not know. Systematic non-
compliance (or never treated) was also associated with acceptability. Individuals who had
taken the treatment once (2.20; p< 0.0001) or more than once (2.33; p< 0.0001) had higher
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Region V (n = 116) Region X (n = 57) Total (n = 390) pvalue
Frequency % Frequency % Frequency % Frequency % Frequency %
Sex
Male 34 30.6% 31 29.2% 25 21.6% 16 28.1% 106 27.2% 0.4275
Female 77 69.4% 75 70.8% 91 78.4% 41 71.9% 284 72.8%
Age
18–25 22 19.8% 16 15.1% 15 12.9% 10 17.5% 63 16.2% 0.5535
26–35 18 16.2% 15 14.2% 29 25.0% 9 15.8% 71 18.2%
36–45 28 25.2% 23 21.7% 21 18.1% 12 21.1% 84 21.5%
46–55 24 21.6% 22 20.8% 26 22.4% 12 21.1% 84 21.5%
56 + 19 17.1% 30 28.3% 25 21.6% 14 24.6% 88 22.6%
Education level attained
No school at all 0 0.0% 1 0.9% 5 4.3% 1 1.8% 7 1.8% <0.0001
Completed primary school 25 22.5% 9 8.5% 46 39.7% 12 21.1% 92 23.6%
Completed middle school 13 11.7% 17 16.0% 5 4.3% 2 3.5% 37 9.5%
Completed secondary school 65 58.6% 64 60.4% 55 47.4% 23 40.4% 207 53.1%
Completed college/university 8 7.2% 14 13.2% 4 3.4% 19 33.3% 45 11.5%
Other 0 0.0% 1 0.9% 1 0.9% 0 0.0% 2 0.5%
Primary source of income
Fishing or farming (agriculture) 3 2.7% 2 1.9% 62 53.4% 0 0.0% 67 17.2% <0.0001
Daily laborer 19 17.1% 7 6.6% 2 1.7% 4 7.0% 32 8.2%
Small scale enterprise 5 4.5% 10 9.4% 3 2.6% 5 8.8% 23 5.9%
Private employment 16 14.4% 47 44.3% 3 2.6% 21 36.8% 87 22.3%
Government/civil servant 5 4.5% 17 16.0% 7 6.0% 22 38.6% 51 13.1%
Other 63 56.8% 23 21.7% 39 33.6% 5 8.8% 130 33.3%
Self-rated understanding of LF
No knowledge (1) 29 26.1% 18 17.0% 30 25.9% 2 3.5% 79 20.3% <0.0001
A little (2) 24 21.6% 19 17.9% 40 34.5% 26 45.6% 109 27.9%
Average (3) 35 31.5% 27 25.5% 17 14.7% 13 22.8% 92 23.6%
Good (4) 6 5.4% 18 17.0% 18 15.5% 11 19.3% 53 13.6%
Very good (5) 17 15.3% 24 22.6% 11 9.5% 5 8.8% 57 14.6%
Mechanism of transmission
Worms 7 6.3% 8 7.5% 19 16.4% 4 7.0% 38 9.7% 0.0391
Mosquitoes 88 79.3% 96 90.6% 94 81.0% 53 93.0% 331 84.9% 0.0220
Water 8 7.2% 11 10.4% 2 1.7% 5 8.8% 26 6.7% �0.0326
Hereditary 0 0.0% 0 0.0% 1 0.9% 0 0.0% 1 0.3% �1.0000
Other 4 3.6% 2 1.9% 0 0.0% 2 3.5% 8 2.1% �0.1358
Don’t Know 21 18.9% 4 3.8% 23 19.8% 3 5.3% 51 13.1% 0.0003
Believes LF to be asymptomatic
Yes 57 51.4% 67 63.2% 52 44.8% 32 56.1% 208 53.3% 0.0002
Maybe 27 24.3% 7 6.6% 17 14.7% 2 3.5% 53 13.6%
No 6 5.4% 15 14.2% 18 15.5% 12 21.1% 51 13.1%
Don’t know 21 18.9% 17 16.0% 29 25.0% 11 19.3% 78 20.0%
Perception of number of people in village with LF
(Continued)
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acceptability scores than those who reported that they have never been treated. Education, age,
sex, and primary source of income were not associated with acceptability in this study.
Sensitivity analysis of the acceptability model
Due to almost 40% missing data on the acceptability score response variables in Region X (as
opposed to<1% missing in all other regions) we conducted a sensitivity analysis to assess the
potential for bias (S1 Table). Our sensitivity model removed the remaining responses from
Region X and examined only data from the more complete region profiles. The same variables
and methods were used in the construction of both models. The final sensitivity model demon-
strated that our primary model was robust to the missing data. Only affirmative Knowledge of
Asymptomatic LF with 0.80 (p = 0.0994) and high Personal Concern about LF 1.75
(p = 0.0343) had changes to variable significance, with only minor differences from the final
model. Sex improved model fit in the sensitivity model but was not significant: 0.58
(p = 0.1069).
Regional analysis of acceptability
High degrees of variation in participants’ self-reported understanding about LF were observed
across the four regions (see Table 1). Surveyed community members in Regions III and V self-
reported lower levels of knowledge, with 26.1% of participants in Region III and 25.9% of par-
ticipants in Region V reporting that they had “no knowledge” of the disease. The trends
observed in this self-reported measure of understanding were similarly observed in partici-
pants’ knowledge of the mechanism of LF transmission. Greater proportions of survey partici-
pants from Regions IV and X (90.6% and 93.0%, respectively) identified “mosquitoes” as the
way LF transmits from person to person, compared to those from Regions III and V (79.3%






Region V (n = 116) Region X (n = 57) Total (n = 390) pvalue
Frequency % Frequency % Frequency % Frequency % Frequency %
None (1) 31 27.9% 9 8.5% 63 54.3% 16 28.1% 119 30.5% †
Few (2) 10 9.0% 26 24.5% 7 6.0% 3 5.3% 46 11.8%
Some (3) 3 2.7% 9 8.5% 7 6.0% 1 1.8% 20 5.1%
Quite a lot (4) 0 0.0% 8 7.5% 2 1.7% 2 3.5% 12 3.1%
Many (5) 0 0.0% 12 11.3% 1 0.9% 0 0.0% 13 3.3%
Don’t know 67 60.4% 42 39.6% 36 31.0% 35 61.4% 180 46.2%
Personal concern about LF
No, not at all (1) 5 4.5% 1 0.9% 3 2.6% 1 1.8% 10 2.6% †
Not really (2) 8 7.2% 6 5.7% 5 4.3% 1 1.8% 20 5.1%
Maybe (3) 2 1.8% 10 9.4% 20 17.2% 2 3.5% 34 8.7%
Yes, a bit (4) 27 24.3% 26 24.5% 39 33.6% 32 56.1% 124 31.8%
Yes, definitely (5) 57 51.4% 63 59.4% 43 37.1% 18 31.6% 181 46.4%
Don’t Know 12 10.8% 0 0.0% 6 5.2% 3 5.3% 21 5.4%
Mean SD Mean SD Mean SD Mean SD Mean SD
Acceptability Score 24.63 ± 3.78 26.68 ± 3.20 29.28 ± 3.97 27.05 ± 2.91 26.92 ± 3.98
� Denotes Fisher’s Exact Test.
† Data is too sparse across categories on these questions to run significance tests.
https://doi.org/10.1371/journal.pntd.0009596.t001
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Table 2. Univariable and adjusted linear regression predicting composite acceptability score in the primary study population.
Variable Univariable Model Adjusted Model
Freq. Coeff. (95% CI) pvalue Coeff. (95% CI) pvalue
Region
Region III 111 REF REF
Region IV 106 2.05 (1.10 ─ 2.99) <0.0001 1.22 (0.39 ─ 2.04) 0.0038
Region V 116 4.65 (3.72 ─ 5.57) <0.0001 3.95 (3.12 ─ 4.78) <0.0001
Region X 57 2.42 (1.29 ─ 3.56) <0.0001 1.40 (0.42 ─ 2.39) 0.0052
Sex
Male 106 REF ─ ─ ─
Female 284 0.96 (0.08 ─ 1.84) 0.0334
Age
18–25 63 REF
26–35 71 1.01 (-0.33 ─ 2.35) 0.1410
36–45 84 0.33 (-0.96 ─ 1.62) 0.6175 ─ ─ ─
46–55 84 0.66 (-0.63 ─ 1.96) 0.3150
56 + 88 0.99 (-0.29 ─ 2.27) 0.1281
Education level attained
Primary School 99 REF
Secondary school 244 -1.12 (-2.04 ─ -0.20) 0.0170 ─ ─ ─
College / University 47 -0.35 (-1.72 ─ 1.02) 0.6188
Primary source of income
Daily Laborer 67 REF
Fishing or Farming (Agriculture) 32 2.39 (0.75 ─ 4.03) 0.0043
Small Scale Enterprise 23 0.30 (-1.78 ─ 2.39) 0.7748 ─ ─ ─
Private Employment 87 0.41 (-1.16 ─ 1.99) 0.6070
Government / Civil servant 51 1.73 (0.01 ─ 3.45) 0.0493
Other 130 0.53 (-0.97 ─ 2.04) 0.4895
Self-rated understanding of LF
No knowledge 79 REF
Some knowledge 109 1.85 (0.72 ─ 2.97) 0.0013
Average knowledge 92 1.05 (-0.12 ─ 2.22) 0.0777 ─ ─ ─
Good knowledge 53 2.19 (0.84 ─ 3.54) 0.0015
Very good knowledge 57 2.52 (1.20 ─ 3.85) 0.0002
Mechanism of transmission�
Worms 38 2.45 (1.14 ─ 3.75) 0.0002 1.39 (0.38 ─ 2.39) 0.0070
Mosquitos 331 1.57 (0.48 ─ 2.66) 0.0048 -2.32 (-4.27 ─ -0.38) 0.0191
Water 26 0.49 (-1.09 ─ 2.08) 0.5398 ─ ─ ─
Hereditary 1 3.08 (-4.71 ─ 10.88) 0.4379 ─ ─ ─
Other 8 -4.01 (-6.76 ─ -1.25) 0.0044 -3.19 (-5.55 ─ -0.83) 0.0081
Don’t know 51 -1.78 (-2.94 ─ -0.63) 0.0025 -2.30 (-4.34 ─ -0.25) 0.0277
Believes LF to be asymptomatic
Yes 208 1.70 (0.70 ─ 2.71) 0.0009 0.87 (0.01 ─ 1.72) 0.0467
Maybe 53 -0.23 (-1.58 ─ 1.11) 0.7336 0.01 (-1.07 ─ 1.09) 0.9830
No 51 2.32 (0.95 ─ 3.68) 0.0009 1.25 (0.18 ─ 2.33) 0.0217
Unsure/Don’t know 78 REF REF
Perception of number of people in village with LF
None 119 2.47 (1.58 ─ 3.35) <0.0001
Few 46 1.05 (-0.19 ─ 2.28) 0.0980
(Continued)
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of LF also varied by region (p = 0.0002). In Region IV, 63.2% of participants understood that
one could be infected with LF and not exhibit symptoms, compared to 56.1%, 51.4%, and
44.8% of participants in Regions X, III, and V, respectively.
Participants’ perceptions of the burden of LF in their communities also appeared to vary by
region. A large proportion of participants in each region reported not knowing how many
people in their village had LF. Only survey respondents from Region IV appeared to identify
LF as a pervasive issue in their community, with 18.8% of respondents reporting there were
“quite a lot” or “many” people in their village with LF. Participants’ personal concern about LF
also varied by region. Community members from Region IV appeared to be the most con-
cerned, with 59.4% of respondents indicating that they were “definitely” concerned about LF.
The proportion of survey respondents that reported being “definitely” concerned in Regions
III, V, and X were 51.4%, 37.1%, and 31.6%, respectively.
Due to the prominence of region as a significant predictor of treatment acceptability in the
aggregate model, as well as the high degree of variation in key variables across region, we con-
structed additional linear regression models to investigate correlates of treatment acceptability
within each region as subgroup analyses (Table 3). Acceptability was not explained uniformly
across the four regions by any single variable. The most commonly impactful variable was sys-
tematic compliance (or never treated) with those having participated in the MDA at least once
being significantly more accepting than those who had not in Regions III, IV, and V by 1.96
Table 2. (Continued)
Variable Univariable Model Adjusted Model
Freq. Coeff. (95% CI) pvalue Coeff. (95% CI) pvalue
Some 20 0.44 (-1.33 ─ 2.21) 0.6263 ─ ─ ─
Lots 12 2.01 (-0.23 ─ 4.24) 0.0786
Many 13 1.55 (-0.60 ─ 3.70) 0.1580
Don’t know 180 REF
Personal concern about LF
No, not at all 10 0.13 (-2.72 ─ 2.98) 0.9270
No, not really 20 0.58 (-1.73 ─ 2.90) 0.6219
Maybe 34 3.92 (1.86 ─ 5.98) 0.0002 ─ ─ ─
Yes, a bit 124 3.25 (1.50 ─ 5.00) 0.0003
Yes, definitely 181 3.98 (2.27 ─ 5.69) <0.0001
Don’t know 21 REF
Number of times taken treatment
Never 75 REF REF
Once 94 3.58 (2.50 ─ 4.66) <0.0001 2.20 (1.23 ─ 3.17) <0.0001
Two or more times 221 4.67 (3.74 ─ 5.60) <0.0001 2.33 (1.46 ─ 3.20) <0.0001
Importance of MDA for community health
Not Important 15 4.33 (1.72 ─ 6.95) 0.0012 1.40 (-0.37 ─ 3.16) 0.1203
Neutral 45 4.58 (2.44 ─ 6.71) <0.0001 3.30 (1.69 ─ 4.91) <0.0001
Important 315 7.05 (5.16 ─ 8.94) <0.0001 1.90 (-0.51 ─ 4.31) 0.1230
Don’t know 15 REF REF
Take LF pills even if not sick
Yes 336 6.45 (4.97 ─ 7.93) <0.0001 2.94 (1.35 ─ 4.53) 0.0003
No 60 3.14 (1.22 ─ 5.06) 0.0014 1.42 (-0.37 ─ 3.21) 0.1203
Don’t know 24 REF REF
� Mechanism of transmission was indicated through a multiple-response category. Regression estimates show indication vs no indication.
https://doi.org/10.1371/journal.pntd.0009596.t002
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Table 3. Univariable and adjusted linear regression predicting composite acceptability score in regional subsets of the primary study population.
Variable Region III Adjusted Model Region IV Adjusted Model Region V Adjusted Model Region X Adjusted Model
Coeff. (95% CI) pvalue Coeff. (95% CI) pvalue Coeff. (95% CI) pvalue Coeff. (95% CI) pvalue
Sex
Male ─ ─ ─ ─ ─ ─ REF ─ ─ ─





26–35 1.49 (-0.11 ─
3.09)
0.0681 -3.12 (-5.44 ─
-0.81)
0.0082
36–45 1.45 (0.01 ─
2.89)
0.0477 ─ ─ ─ ─ ─ ─ -2.57 (-4.63 ─
-0.52)
0.0142
46–55 1.36 (-0.14 ─
2.85)
0.0747 -0.85 (-2.95 ─
1.24)
0.4250
56 + 2.23 (0.67 ─
3.78)
0.0050 -0.34 (-2.45 ─
1.77)
0.7505
Self-rated understanding of LF
No knowledge REF REF
Some knowledge -0.96 (-2.68 ─
0.76)
0.2729 4.76 (0.97 ─
8.55)
0.0138
Average knowledge ─ ─ ─ -2.11 (-3.67 ─
-0.54)
0.0082 ─ ─ ─ 3.38 (-0.52 ─
7.28)
0.0895
Good knowledge -2.26 (-4.13 ─
-0.40)
0.0174 2.82 (-1.01 ─
6.66)
0.1493
Very good knowledge -0.64 (-2.27 ─
0.99)
0.4405 5.96 (1.81 ─
10.11)
0.0049
Mechanism of transmission ‡
Worms 2.50 (0.92 ─
4.08)
0.0019
Mosquitos ─ ─ ─ -1.99 (-4.08 ─
0.10)
0.0614 ─ ─ ─
Don’t know -4.60 (-7.81 ─
-1.39)
0.0050
Believes LF to be asymptomatic
Yes 1.74 (0.34 ─
3.13)
0.0146 2.34 (0.87 ─
3.81)
0.0019
Maybe 0.85 (-0.68 ─
2.39)
0.2762 1.96 (-0.48 ─
4.41)
0.1161 ─ ─ ─ ─ ─ ─
No 1.11 (-1.23 ─
3.44)
0.3536 3.33 (1.56 ─
5.09)
0.0002
Unsure/Don’t know REF REF
Number of times taken treatment
Never REF REF REF
Once 1.96 (0.28 ─
3.65)
0.0219 3.43 (2.00 ─
4.86)
<0.0001 4.09 (1.35 ─
6.82)
0.0034 ─ ─ ─
Two or more times 2.16 (0.67 ─
3.64)
0.0045 1.45 (0.24 ─
2.67)
0.0189 4.65 (2.62 ─
6.67)
<0.0001
Importance of MDA for community
health
Not Important � REF REF
Neutral -1.24 (-3.56 ─
1.09)
0.2965 † † ─ ─ ─
(Continued)
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(p = 0.0219), 3.43 (p< 0.0001), and 4.09 (p = 0.0034) points respectively. Knowledge of asymp-
tomatic LF was significantly associated with acceptability in Region III by 1.74 points
(p = 0.0146) and Region IV with 2.34 points (p = 0.0019) compared to those who were unsure.
This closely tracks the knowledge that participants should take LF pills even when they are not
symptomatic: those who answered yes in Region III were 3.91 (p = 0.0003) points higher on
average compared to those who don’t know, and Region IV participants who answered yes
scored 1.83 (p = 0.0346) points higher than those who responded no. Age was significantly
associated with acceptability in Regions III and X, although the age groups of concern were in
disagreement. Perceived importance of MDA for community health was strongly associated
with acceptability in Regions IV and V, showing 3.80 (p< 0.0001) and 2.42 (p = 0.0006) point
increases, respectively. Importance of the MDA for community health was also retained in the
final model in Region III for model fit. Sex was important in Region V only, with females hav-
ing higher acceptability scores by 1.53 (p = 0.0452) points. Level of education, primary source
of income, and perception of LF prevalence in the village were not significant in any region,
adjusting for other covariates.
Analysis of key sex differences
Sex was associated with self-reported knowledge of LF (p = 0.0133). Of surveyed men, 27.4%
reported having no knowledge about LF, compared to only 17.6% of females (Table 4). No sig-
nificant differences were observed between males and females in understanding of how LF is
transmitted or its asymptomatic nature. However, there were some variations between sex in
the “don’t know” response to LF transmission and asymptomatic nature of LF with males
reporting “don’t know” more frequently than females did. Perceptions of the burden of LF and
levels of personal concern about the disease did not vary across sex, however males reported
“don’t know” more frequently than females to a question about personal concern for LF. In a
subset of participants who had participated in a previous MDA, there were no observed differ-
ences between how males or females felt about the number of pills they received (p = 0.3049),
with males reporting more “don’t know” responses than women. Due to a lack of association
with key variables, no model was constructed for sex.
Table 3. (Continued)
Variable Region III Adjusted Model Region IV Adjusted Model Region V Adjusted Model Region X Adjusted Model
Coeff. (95% CI) pvalue Coeff. (95% CI) pvalue Coeff. (95% CI) pvalue Coeff. (95% CI) pvalue
Important 0.74 (-1.63 ─
3.11)
0.5408 3.80 (2.15 ─
5.44)
<0.0001 2.42 (1.04 ─
3.80)
0.0006
Don’t know REF � †
Take LF pills even if not sick
Yes 3.91 (1.77 ─
6.05)
0.0003 1.83 (0.13 ─
3.52)
0.0346
No 2.79 (0.11 ─
5.47)
0.0416 REF ─ ─ ─ ─ ─ ─
Don’t know REF �
� No data in this category.
† Collapsed into “Not important.”
‡ Mechanism of transmission was indicated through a multiple-response category. Regression estimates show indication vs no indication.
§ Education level attained, primary source of income, and perception of number of people in village with LF were included in the multivariable analyses but were not
significant in any adjusted model.
https://doi.org/10.1371/journal.pntd.0009596.t003
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Table 4. Descriptive analysis of key variables by sex in the primary study population.
Variable Men (n = 106) Women (n = 284) Total (n = 390) pvalue
Frequency % Frequency % Frequency %
Self-rated understanding of LF
No knowledge (1) 29 27.4% 50 17.6% 79 20.3% 0.0133
A little (2) 26 24.5% 83 29.2% 109 27.9%
Average (3) 32 30.2% 60 21.1% 92 23.6%
Good (4) 8 7.5% 45 15.8% 53 13.6%
Very good (5) 11 10.4% 46 16.2% 57 14.6%
Mechanism of LF transmission †
Worms 7 6.6% 31 10.9% 38 9.7% 0.2015
Mosquitoes 84 79.2% 247 87.0% 331 84.9% 0.0582
Water 6 5.7% 20 7.0% 26 6.7% 0.6265
Hereditary 1 0.9% 0 0.0% 1 0.3% �0.2718
Other 5 4.7% 3 1.1% 8 2.1% �0.0371
Don’t Know 16 15.1% 35 12.3% 51 13.1% 0.4703
Believes LF to be asymptomatic
Yes 49 46.2% 159 56.0% 208 53.3% 0.3758
Maybe 16 15.1% 37 13.0% 53 13.6%
No 17 16.0% 34 12.0% 51 13.1%
Don’t know 24 22.6% 54 19.0% 78 20.0%
Perception of number of people in village with LF
None (1) 36 34.0% 83 29.2% 119 30.5% �0.7622
Few (2) 10 9.4% 36 12.7% 46 11.8%
Some (3) 4 3.8% 16 5.6% 20 5.1%
Quite a lot (4) 3 2.8% 9 3.2% 12 3.1%
Many (5) 5 4.7% 8 2.8% 13 3.3%
Don’t know 48 45.3% 132 46.5% 180 46.2%
Personal concern about LF
No, not at all (1) 4 3.8% 6 2.1% 10 2.6% �0.2557
Not really (2) 8 7.5% 12 4.2% 20 5.1%
Maybe (3) 10 9.4% 24 8.5% 34 8.7%
Yes, a bit (4) 30 28.3% 94 33.1% 124 31.8%
Yes, definitely (5) 45 42.5% 136 47.9% 181 46.4%
Don’t Know 9 8.5% 12 4.2% 21 5.4%
Feeling about the number of pills received ‡
Very happy 12 16.4% 48 21.2% 60 20.1% �0.3049
Happy 16 21.9% 70 31.0% 86 28.8%
Neutral 33 45.2% 78 34.5% 111 37.1%
Unhappy 5 6.8% 16 7.1% 21 7.0%
Very unhappy 5 6.8% 12 5.3% 17 5.7%
Don’t know 2 2.7% 2 0.9% 4 1.3%
Number of times taken treatment
Never 23 21.7% 52 18.3% 75 19.2% 0.4501
� One time 83 78.3% 232 81.7% 315 80.8%
� Denotes Fisher’s Exact Test.
† Mechanism of transmission was indicated through a multiple-response category. Percentages may exceed 100%.
‡ Question was only asked to those who said they remember the previous mass drug administration.
https://doi.org/10.1371/journal.pntd.0009596.t004
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Analysis of patterns of never treated or systematic non-compliance
Systematic non-compliance with treatment is a self-reported measure whereby the participant
reported that they have never taken treatment for LF. Survey participants reported high com-
pliance with the most recent MDA and previous rounds of MDA (Table 5). Across all regions,
19.2% of participants self-identified as having never been treated during an MDA. Region IV
had the greatest proportion of systematic non-compliers, with 28.3% of community members
saying that they had never taken any treatment for LF during MDA. Some knowledge indica-
tors differed between individuals who had never been treated and those who reported to have
been treated before (either once or more than once). Self-rated understanding of LF was asso-
ciated with ever participating in an MDA (p< 0.0001). Over 42% of those who had never par-
ticipated in MDA reported having “no knowledge” of LF, compared to only 14.9% of those
who had previously participated in MDA. A greater proportion of those who had previously
participated in MDA also understood that the disease was spread by mosquitoes compared to
those who had never participated (87.6% to 73.3%, p = 0.0019). Similarly, a greater proportion
of those who had never participated in MDA reported not knowing how LF was transmitted
compared to those who had previously participated (24.0% to 10.5%, p = 0.0018). Those who
reported having “no knowledge” of LF did not know how LF was spread and who were not as
personally concerned about the disease also tended to be never treated. When asked if the
respondent was personally concerned about LF, 20% of the never treated individuals reported
they were not concerned, versus only 4.8% of individuals having been treated at least once. A
higher proportion of individuals who reported “don’t know” to their level of concern about LF
were found to have never been treated, as opposed to those who had taken the treatment once,
or more than once. Community members who had never been treated during MDA did not
perceive the LF burden in their communities differently than those who had previously partici-
pated (p = 0.5726).
Multivariable analysis (Table 6) was conducted to understand the relationship between the
never treated during MDA compared to those who had been treated at least once (n = 390).
The odds of never treatment during MDA for LF were higher in Regions III (Adjusted Odds
Ratio 6.97; p = 0.0076) and IV (AOR 13.51; p = 0.0002) compared to Region X. Those who did
not know the mode of transmission for LF were nearly three times as likely to have never been
treated during MDA (AOR 2.76; p = 0.0404) compared to those who indicated some theory of
transmission. Having no knowledge of asymptomatic LF was associated with lower likelihood
of treatment (AOR 3.34; p = 0.0417) compared to those who were unsure. Similarly, those who
expressed no personal concern about LF were more likely to have never been treated during
MDA than those who “don’t know” if they were concerned (AOR 7.15; p = 0.0401). Individu-
als who reported that MDA was important for community health (AOR 0.10; p = 0.0140) or
who were neutral (AOR 0.16; p = 0.0711) in their response also were less likely to have never
been treated than those who reported “don’t know.” Finally, individuals who believed that you
should take the LF pills even if you are not sick were less likely to have never been treated
(AOR 0.14; p = 0.0094) than individuals who responded, “don’t know” to this statement. Age,
sex, level of education, primary source of income, perceived understanding of lymphatic filari-
asis, and perception of LF prevalence in their village were not related to self-reported history
of treatment.
MDA participant subset analysis
Community members who remembered the most recent distribution (n = 289) were asked a
series of questions relating to their experience with the MDA (Table 7). Most of these respon-
dents (87.2%) stated that other members of their household also participated in the MDA.
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Table 5. Descriptive analysis of key demographic and knowledge variables across participants’ historical compliance with MDA in the primary study population.
Variable Never Treated Treated�Once Total (n = 390) pvalue
Frequency % Frequency % Frequency %
Region
Region III 30 40.0% 81 25.7% 111 28.5% <0.0001
Region IV 30 40.0% 76 24.1% 106 27.2%
Region V 12 16.0% 104 33.0% 116 29.7%
Region X 3 4.0% 54 17.1% 57 14.6%
Sex
Male 23 30.7% 83 26.3% 106 27.2% 0.4501
Female 52 69.3% 232 73.7% 284 72.8%
Age
18–25 12 16.0% 51 16.2% 63 16.2% 0.6374
26–35 18 24.0% 53 16.8% 71 18.2%
36–45 16 21.3% 68 21.6% 84 21.5%
46–55 13 17.3% 71 22.5% 84 21.5%
56 + 16 21.3% 72 22.9% 88 22.6%
Level of education
No school at all 2 2.7% 5 1.6% 7 1.8% �0.9123
Completed primary school 15 20.0% 77 24.4% 92 23.6%
Completed middle school 7 9.3% 30 9.5% 37 9.5%
Completed secondary school 42 56.0% 165 52.4% 207 53.1%
Completed college/university 9 12.0% 36 11.4% 45 11.5%
Other 0 0.0% 2 0.6% 2 0.5%
Self-rated understanding of LF
No knowledge 32 42.7% 47 14.9% 79 20.3% <0.0001
Some knowledge 16 21.3% 93 29.5% 109 27.9%
Average knowledge 13 17.3% 79 25.1% 92 23.6%
Good knowledge 2 2.7% 51 16.2% 53 13.6%
Very good knowledge 12 16.0% 45 14.3% 57 14.6%
Mechanism of LF transmission †
Worms 7 9.3% 31 9.8% 38 9.7% 0.8939
Mosquitoes 55 73.3% 276 87.6% 331 84.9% 0.0019
Water 3 4.0% 23 7.3% 26 6.7% 0.3029
Hereditary 0 0.0% 1 0.3% 1 0.3% �0.8077
Other 3 4.0% 5 1.6% 8 2.1% �0.1846
Don’t Know 18 24.0% 33 10.5% 51 13.1% 0.0018
Believes LF to be asymptomatic
Yes 33 44.0% 175 55.6% 208 53.3% 0.3178
Maybe 11 14.7% 42 13.3% 53 13.6%
No 12 16.0% 39 12.4% 51 13.1%
Don’t know 19 25.3% 59 18.7% 78 20.0%
Perception of number of people in village with LF
None 18 24.0% 101 32.1% 119 30.5% �0.5726
Few 8 10.7% 38 12.1% 46 11.8%
Some 4 5.3% 16 5.1% 20 5.1%
Lots 4 5.3% 8 2.5% 12 3.1%
Many 2 2.7% 11 3.5% 13 3.3%
Don’t know 39 52.0% 141 44.8% 180 46.2%
(Continued)
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Overall, 49.0% reported feeling “happy” or “very happy” about the number of pills they
received, while 36.9% reported feeling “neutral.” Some regional variation was observed in this
variable. Regions III and V had the largest proportions of community members reporting that
they were “happy” or “very happy” with the number of pills they received (55.1% and 58.2%),
while Region X had the smallest (28.9%). Region X also had the greatest proportion of survey
respondents indicating they were “unhappy” or “very unhappy” with the number of pills they
received (23.1%) compared to the other regions (5.0%, 14.5%, and 12.3% in Regions III, VI,
and V, respectively). Some regional variation was observed.
We used this subset of participants who had taken the LF treatment previously to explore
the attitudes related to compliance with the 2018 DEC/Albendazole MDA. As with the accept-
ability model, region was an important factor in compliance with treatment (Table 8). Those
in Regions IV, V, and X had higher acceptability scores than individuals in Region III (1.16
(p = 0.0204), 3.27 (p< 0.0001), and 1.47 (p = 0.0045) points higher, respectively). Individuals
who understood worms were implicated in LF transmission also scored 1.14 (p = 0.0342)
points higher. Those who perceived that there was no LF in their village had higher scores
(1.03; p = 0.0090) compared to those who did not know about LF prevalence in the commu-
nity. Finally, results indicated that those who believed that the treatment was very safe were
more accepting (1.59; p = 0.0695) than those who did not know if the LF drugs were safe or
not.
Discussion
In preparation for the 2019 MDA with IDA regimen, the research team undertook a nested
acceptability study within a larger sentinel mapping study to assess the coverage, compliance,
and acceptability of the 2018 MDA with DEC/Albendazole in Guyana. The study findings
were then used to inform the rollout of the MDA with IDA in 2019 and to provide a baseline
Table 5. (Continued)
Variable Never Treated Treated�Once Total (n = 390) pvalue
Frequency % Frequency % Frequency %
Personal concern about LF
No, not at all 6 8.0% 4 1.3% 10 2.6 �0.0004
No, not really 9 12.0% 11 3.5% 20 5.1%
Maybe 4 5.3% 30 9.5% 34 8.7%
Yes, a bit 21 28.0% 103 32.7% 124 31.8%
Yes, definitely 28 37.3% 153 48.6% 181 46.4%
Don’t know 7 9.3% 14 4.4% 21 5.4%
Importance of MDA for community health
Not Important 7 9.3% 8 2.5% 15 3.8% �<0.0001
Neutral 12 16.0% 33 10.5% 45 11.5%
Important 44 58.7% 271 86.0% 315 80.8%
Don’t know 12 16.0% 3 1.0% 15 3.8%
Take LF pills even if not sick
Yes 46 61.3% 290 92.1% 336 86.2% <0.0001
No 13 17.3% 17 5.4% 30 7.7%
Don’t know 16 21.3% 8 2.5% 24 6.2%
� Denotes Fisher’s Exact Test.
† Mechanism of transmission was indicated through a multiple-response category. Percentages may exceed 100%.
https://doi.org/10.1371/journal.pntd.0009596.t005
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Table 6. Univariable and adjusted logistic regression predicting odds of systematic non-compliance (never treated) with MDA in the primary study population.
Variable Univariable Model Adjusted Model
Freq. OR (95% CI) pvalue AOR (95% CI) pvalue
Region
Region III 111 6.67 (1.94 ─ 22.94) 0.0026 6.97 (1.68 ─ 29.00) 0.0076
Region IV 106 7.11 (2.06 ─ 24.48) 0.0019 13.51 (3.40 ─ 53.67) 0.0002
Region V 116 2.08 (0.56 ─ 7.68) 0.2731 1.95 (0.42 ─ 8.97) 0.3926
Region X 57 REF
Sex
Male 106 1.24 (0.71 ─ 2.15) 0.4506 ─ ─ ─
Female 284 REF
Age
18–25 63 1.06 (0.46 ─ 2.43) 0.8926
26–35 71 1.53 (0.71 ─ 3.27) 0.2747
36–45 84 1.06 (0.49 ─ 2.28) 0.8840 ─ ─ ─
46–55 84 0.82 (0.37 ─ 1.84) 0.6360
56 + 88 REF
Education level attained
Primary School 99 REF
Secondary school 244 1.21 (0.66 ─ 2.23) 0.5360 ─ ─ ─
College / University 47 1.14 (0.47 ─ 2.80) 0.7706
Primary source of income
Daily Laborer 67 REF
Fishing or Farming (Agriculture) 32 2.52 (0.89 ─ 7.15) 0.0821
Small Scale Enterprise 23 1.36 (0.37 ─ 4.91) 0.6421
Private Employment 87 1.80 (0.76 ─ 4.29) 0.1837 ─ ─ ─
Government / Civil servant 51 1.20 (0.43 ─ 3.36) 0.7301
Other 130 1.61 (0.71 ─ 3.67) 0.2562
Self-rated understanding of LF
No/Some knowledge 188 2.35 (1.23 ─ 4.50) 0.0099
Average knowledge 92 1.13 (0.50 ─ 2.54) 0.7705 ─ ─ ─
Good/Very good knowledge 110 REF
Mechanism of transmission �
Worms 38 0.94 (0.40 ─ 2.23) 0.8940 ─ ─ ─
Mosquitos 276 0.39 (0.21 ─ 0.72) 0.0025 ─ ─ ─
Don’t know 51 2.70 (1.42 ─ 5.12) 0.0024 2.76 (1.05 ─ 7.26) 0.0404
Believes LF to be asymptomatic
Yes 208 0.59 (0.31 ─ 1.11) 0.0996 1.23 (0.46 ─ 3.25) 0.6795
Maybe 53 0.81 (0.35 ─ 1.89) 0.6302 1.06 (0.32 ─ 3.50) 0.9217
No 51 0.96 (0.42 ─ 2.19) 0.9141 3.34 (1.05 ─ 10.66) 0.0417
Unsure/Don’t know 78 REF
Perception of number of people in village with LF
None/Few 165 0.68 (0.39 ─ 1.17) 0.1624
Some 20 0.90 (0.29 ─ 2.86) 0.8634 ─ ─ ─
Lots/Many 25 1.14 (0.43 ─ 3.05) 0.7918
Don’t know 180 REF
Personal concern about LF
No, not at all/No, not really 30 2.00 (0.63 ─ 6.35) 0.2397 7.15 (1.09 ─ 46.77) 0.0401
Maybe 34 0.27 (0.07 ─ 1.06) 0.0610 0.83 (0.11 ─ 6.03) 0.8519
(Continued)
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Table 6. (Continued)
Variable Univariable Model Adjusted Model
Freq. OR (95% CI) pvalue AOR (95% CI) pvalue
Yes, a bit/Yes, definitely 305 0.38 (0.15 ─ 1.00) 0.0493 2.29 (0.41 ─ 12.88) 0.3458
Don’t know 21 REF
Importance of MDA for community health
Not Important 15 0.22 (0.04 ─ 1.11) 0.0662 1.23 (0.14 ─ 11.08) 0.8565
Neutral 45 0.09 (0.02 ─ 0.38) 0.0010 0.16 (0.02 ─ 1.17) 0.0711
Important 315 0.04 (0.01 ─ 0.15) <0.0001 0.10 (0.02 ─ 0.63) 0.0140
Don’t know 15 REF
Take LF pills even if not sick
Yes 336 0.08 (0.03 ─ 0.20) <0.0001 0.14 (0.03 ─ 0.62) 0.0094
No 30 0.38 (0.13 ─ 1.17) 0.0908 0.54 (0.11 ─ 2.73) 0.4597
Don’t know 24 REF
� Mechanism of transmission was indicated through a multiple-response category. Regression estimates show indication vs no indication.
https://doi.org/10.1371/journal.pntd.0009596.t006
Table 7. Descriptive analysis of key variables in a subset of the primary study population who have previously participated in an MDA.
Variable Region III (n = 80) Region IV (n = 68) Region V (n = 98) Region X (n = 52) Total (n = 298)
Frequency % Frequency % Frequency % Frequency % Frequency %
Other members of the household took pills at the same time
Yes 68 85.0% 61 89.7% 95 96.9% 36 69.2% 260 87.2%
No 3 3.8% 4 5.9% 2 2.0% 8 15.4% 17 5.7%
Don’t know 9 11.3% 3 4.4% 1 1.0% 8 15.4% 21 7.0%
Feeling about the number of pills received
Very happy 25 31.3% 17 25.0% 14 14.3% 4 7.7% 60 20.1%
Happy 19 23.8% 13 19.1% 43 43.9% 11 21.2% 86 28.9%
Neutral 31 38.8% 28 41.2% 29 29.6% 22 42.3% 110 36.9%
Unhappy 2 2.5% 6 8.8% 8 8.2% 5 9.6% 21 7.0%
Very unhappy 2 2.5% 4 5.9% 4 4.1% 7 13.5% 17 5.7%
Don’t know/Unsure 1 1.3% 0 0.0% 0 0.0% 3 5.8% 4 1.3%
Description of Information regarding the LF treatment
Not useful 5 6.3% 1 1.5% 0 0.0% 2 3.8% 8 2.7%
A little useful 10 12.5% 0 0.0% 2 2.0% 2 3.8% 14 4.7%
Neutral 26 32.5% 4 5.9% 4 4.1% 6 11.5% 40 13.4%
Useful 11 13.8% 33 48.5% 34 34.7% 18 34.6% 96 32.2%
Very useful 24 30.0% 28 41.2% 58 59.2% 18 34.6% 128 43.0%
Don’t know/Didn’t receive info 4 5.0% 2 2.9% 0 0.0% 6 11.5% 12 4.0%
Opinion on LF drug safety
Very dangerous 0 0.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0%
Dangerous 1 1.3% 2 2.9% 3 3.1% 1 1.9% 7 2.3%
Neutral 17 21.3% 6 8.8% 8 8.2% 7 13.5% 38 12.8%
Safe 13 16.3% 13 19.1% 13 13.3% 26 50.0% 65 21.8%
Very safe 47 58.8% 44 64.7% 73 74.5% 13 25.0% 177 59.4%
Don’t know 2 2.5% 3 4.4% 1 1.0% 5 9.6% 11 3.7%
https://doi.org/10.1371/journal.pntd.0009596.t007
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Table 8. Univariable and adjusted linear regression predicting composite acceptability score in a subset of the primary study population who have previously par-
ticipated in an MDA.
Variable Univariable Model Adjusted Model
Freq. Coeff. (95% CI) pvalue Coeff. (95% CI) pvalue
Region
Region III 80 REF REF
Region IV 68 1.24 (0.29 ─ 2.19) 0.0105 1.16 (0.18 ─ 2.14) 0.0204
Region V 98 4.04 (3.17 ─ 4.90) <0.0001 3.27 (2.41 ─ 4.14) <0.0001
Region X 52 1.13 (0.10 ─ 2.15) 0.0309 1.47 (0.45 ─ 2.48) 0.0045
Sex
Male 73 REF
Female 225 0.96 (0.08 ─ 1.84) 0.0330 ─ ─ ─
Age
18–25 48 REF
26–35 50 0.86 (-0.47 ─ 2.18) 0.2056
36–45 66 0.66 (-0.58 ─ 1.91) 0.2958 ─ ─ ─
46–55 66 0.98 (-0.26 ─ 2.22) 0.1218
56 + 68 0.88 (-0.36 ─ 2.11) 0.1650
Education level attained
Primary School 78 REF
Secondary school 184 -1.19 (-2.06 ─ -0.31) 0.0082 ─ ─ ─
College / University 36 -1.27 (-2.58 ─ 0.04) 0.0567
Primary source of income
Daily Laborer 55 REF
Fishing or Farming (Agriculture) 22 2.86 (1.27 ─ 4.46) 0.0004
Small Scale Enterprise 18 0.78 (-1.23 ─ 2.79) 0.4448 ─ ─ ─
Private Employment 63 0.12 (-1.45 ─ 1.68) 0.8843
Government / Civil servant 41 1.20 (-0.47 ─ 2.87) 0.1580
Other 99 0.88 (-0.61 ─ 2.37) 0.2447
Self-rated understanding of LF
No knowledge 41 REF
Some knowledge 91 -0.16 (-1.37 ─ 1.06) 0.8015
Average knowledge 77 -1.40 (-2.65 ─ -0.15) 0.0282 ─ ─ ─
Good knowledge 45 -0.42 (-1.82 ─ 0.97) 0.5538
Very good knowledge 44 0.42 (-0.99 ─ 1.82) 0.5621
Mechanism of transmission †
Worms 30 2.19 (0.95 ─ 3.43) 0.0006 1.14 (0.08 ─ 2.19) 0.0342
Mosquitos 262 -0.06 (-1.23 ─ 1.11) 0.9140 ─ ─ ─
Water 22 -0.46 (-1.91 ─ 1.00) 0.5390 ─ ─ ─
Hereditary 1 �
Other 5 -4.10 (-7.03 ─ -1.17) 0.0061 -2.53 (-5.15 ─ 0.09) 0.0584
Don’t know 30 0.11 (-1.15 ─ 1.38) 0.8619
Believes LF to be asymptomatic
Yes 168 0.32 (-0.69 ─ 1.34) 0.5309
Maybe 42 -1.17 (-2.50 ─ 0.16) 0.0842 ─ ─ ─
No 35 1.63 (0.23 ─ 3.03) 0.0221
Unsure/Don’t know 53 REF
Perception of number of people in village with LF
None 98 2.22 (1.39 ─ 3.06) <0.0001 1.03 (0.26 ─ 1.80) 0.0090
(Continued)
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Table 8. (Continued)
Variable Univariable Model Adjusted Model
Freq. Coeff. (95% CI) pvalue Coeff. (95% CI) pvalue
Few 37 0.27 (-0.90 ─ 1.44) 0.6507 0.25 (-0.81 ─ 1.31) 0.6463
Some 16 0.31 (-1.35 ─ 1.98) 0.7128 -0.25 (-1.70 ─ 1.19) 0.7299
Lots 8 1.25 (-1.04 ─ 3.54) 0.2844 0.37 (-1.62 ─ 2.37) 0.7148
Many 8 0.63 (-1.66 ─ 2.91) 0.5925 0.38 (-1.72 ─ 2.48) 0.7245
Don’t know 131 REF REF
Personal concern about LF
No, not at all/No, not really 14 3.11 (0.56 ─ 5.65) 0.0166 3.11 (0.56 ─ 5.65) 0.0166
Maybe 27 3.53 (1.28 ─ 5.77) 0.0021 3.53 (1.28 ─ 5.77) 0.0021
Yes, a bit 99 2.32 (0.34 ─ 4.29) 0.0216 2.32 (0.34 ─ 4.29) 0.0216
Yes, definitely 146 2.75 (0.81 ─ 4.69) 0.0055 2.75 (0.81 ─ 4.69) 0.0055
Don’t know 12 REF REF
Other members of the household took pills at the same time
Yes 250 -1.15 (-2.79 ─ 0.49) 0.1690
No 17 -1.07 (-2.55 ─ 0.42) 0.1584 ─ ─ ─
Don’t know 21 REF
Feeling about the number of pills received
Very happy 60 2.37 (-0.95 ─ 5.68) 0.1621
Happy 86 2.25 (-1.04 ─ 5.54) 0.1796
Neutral 110 0.90 (-2.38 ─ 4.17) 0.5915 ─ ─ ─
Unhappy 21 0.56 (-2.95 ─ 4.06) 0.7544
Very unhappy 17 1.51 (-2.06 ─ 5.09) 0.4057
Don’t know/Unsure 4 REF
Description of Information regarding the LF treatment
Not useful 8 -0.25 (-3.06 ─ 2.56) 0.8615
A little useful 14 0.54 (-1.88 ─ 2.96) 0.6644
Neutral 40 0.28 (-1.75 ─ 2.30) 0.7901 ─ ─ ─
Useful 96 2.00 (0.12 ─ 3.88) 0.0374
Very useful 128 3.22 (1.36 ─ 5.08) 0.0007
Don’t know/Didn’t receive info 12 REF
Opinion on LF drug safety
Very dangerous/Dangerous 7 0.30 (-2.70 ─ 3.30) 0.8453 0.00 (-2.75 ─ 2.74) 0.9982
Neutral 38 -0.61 (-2.74 ─ 1.51) 0.5707 -0.65 (-2.51 ─ 1.21) 0.4931
Somewhat safe 65 0.91 (-1.11 ─ 2.94) 0.3771 0.56 (-1.19 ─ 2.31) 0.5325
Very safe 177 2.41 (0.48 ─ 4.34) 0.0143 1.59 (-0.13 ─ 3.30) 0.0695
Don’t know 11 REF REF
Importance of MDA for community health
Not Important 5 -2.80 (-5.94 ─ 0.34) 0.0808
Neutral 30 -1.22 (-4.16 ─ 1.71) 0.4145 ─ ─ ─
Important 261 -2.20 (-7.64 ─ 3.24) 0.4283
Don’t know 2 REF
Take LF pills even if not sick
Yes 277 2.70 (0.36 ─ 5.03) 0.0238
No 13 1.75 (-1.18 ─ 4.68) 0.2416 ─ ─ ─
Don’t know 8 REF
� No data in this category.
† Mechanism of transmission was indicated through a multiple-response category. Regression estimates show indication vs no indication.
https://doi.org/10.1371/journal.pntd.0009596.t008
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for further data collection to assess changes in coverage, compliance, and acceptability. The
survey used a mean acceptability score as the primary outcome of interest in addition to
known knowledge and perception indicators. In this study, across all four regions, acceptabil-
ity of the 2018 MDA was above the threshold.
Region was an important determinant for both compliance with treatment and acceptabil-
ity. Variation was reported across the four regions for many key indicators. Regions III and V
reported lower levels of knowledge and higher proportions of “don’t knows” for key variables.
In contrast, Region IV, where the capital Georgetown is located, reported some of the highest
levels of understanding about LF and its transmission despite having the highest number of
noncompliers in the last MDA (2018) and highest numbers of never treated individuals (or
systematic noncompliers) along with Region III. This implies that knowledge alone is not suffi-
cient to drive high treatment coverage. These regional variations reveal the need for more tai-
lored approaches to the planning and social mobilization activities carried out prior to MDA.
While the national program can provide support and technical guidance, regional approaches
can consider past population behavior vis à vis MDA as well as contextual specifications. Stud-
ies reporting challenges with MDA in urban areas have suggested that specific strategies are
needed in these contexts, given the complex populations, increased mobility, migration and
fractured social structures found in more dense populations [38–41]. With the introduction of
IDA in Guyana, specific attention can be made to the lower levels of knowledge in Regions III
and V, and additional and novel distribution practices can be considered in Georgetown
(Region IV) that build on past experiences with MDA to improve coverage. A specific
approach to identify never treated individuals during MDA by drug distribution teams should
be encouraged to ensure these individuals have their questions answered and are encouraged
to participate in MDA.
One of the considerations for the introduction of IDA is the increased number of pills that
community members will receive with the addition of ivermectin tablets to DEC and Albenda-
zole. While the global acceptability study did not find any association of number of pills with
acceptability [23] it remains a factor that many programs would like to investigate prior to the
introduction of IDA. In this Guyanese study, the number of pills in DA MDA was not an issue
associated with acceptability. This finding should reassure that additional tablets will not likely
be faced with resistance in the community; however, awareness and education about the ratio-
nale for the inclusion of ivermectin is recommended to encourage uptake in the community
and to signal the added value of ivermectin to the treatment protocols.
Identifying the proportion of people who have never been treated during MDA is needed
so that programs understand who has missed treatment over the course of MDA [42]. This
information can then be used to reorient subsequent rounds, as needed, to ensure these indi-
viduals are reached with MDA. This dataset provides some insight into barriers to individual
participation which could be applied operationally in Guyana. Region remains an important
indicator associated with never treatment or systematic non-compliance. The relationship
between those who have never been treated during MDA and acceptability is expected; e.g.
those who never take LF treatment also have lower levels of acceptability. This relationship
serves to validate the use of both variables as indicators of importance to understand commu-
nity response to MDA. For those who have never been treated in this dataset, it is noticeable
that levels of key knowledge indicators and general perception of risk for LF are lower than for
those who have taken treatment in the past. The relationship is striking between those who
report that they “don’t know” as opposed to those who made a choice on a question (correct or
incorrect / yes or no). There were higher proportions of systematic noncompliers who
reported that they “did not know” if they were concerned about LF or how the disease was
spread. This may indicate indifference, lack of knowledge, or a lack of access to information.
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This phenomenon carried into other analyses whereby the “don’t know” category acted dif-
ferently than those who had taken a position, even a neutral position. Enumerators in this
study were trained not to offer the option of “don’t know” while administering the question-
naire, to minimize the use of the “don’t know” response in the dataset. This was done so that a
“don’t know” response was not given by respondents out of laziness or to please interviewers
but was used to elucidate when respondents did not know the response. “Don’t know” catego-
ries in health behavior research can be problematic in analysis and can reduce validity of the
findings [43]. Regardless, evidence shows that there is more nuance needed in our understand-
ing of this response [43]. In this dataset, the interpretation of the “don’t know” category is con-
sistent and seems to suggest that it is part of a linear progression, whereby “don’t know”
represents a lower understanding or awareness compared to individuals who have formed an
opinion (either affirmative or negative). For the purposes of the Guyanese program, further
analysis of the “don’t know” responses may provide some direction to tailor future social
mobilization activities.
A few key messages emerged that were related to acceptability, compliance, and history of
compliance. They included: the need to take the treatment if not sick; the importance of MDA
for community health; LF drugs are safe and; knowing about LF transmission. Some of these
messages have been shown to be important in other global studies and confirm that scientific
or medical knowledge alone may not be the most important in motivating behavior to comply
with treatment. In Indonesia, for example, drug safety and understanding the importance of
MDA for the community were shown to be associated with compliance in two districts [44].
Other studies have shown that some understanding about LF transmission is important for
compliance [45–48]. Further understanding about how these messages resonate across sex, age
groups and regions would help to refine upcoming health information campaigns prior to
MDA delivery.
Based on these data, recommendations for the Guyana LF program suggest that a regional
perspective is needed to promote acceptability, coverage, and compliance with LF treatment.
The results from this study can be used to develop a more tailored approach to community
mobilization, assessing gaps and building on strengths of the current activities to provide a
solid awareness campaign prior to IDA rollout. The number of pills will not likely be an issue
based on these data, however messaging about the addition of ivermectin will be important
based on experiences from other IDA rollout countries (personal communication A Krentel).
The detailed analysis of those who have never been treated provides an insight into how spe-
cific messages and distribution approaches may be oriented to ensure that these individuals
will be reached with the 2019 MDA with IDA. The measurements of acceptability and system-
atic non-compliance can also serve as a baseline from which to assess the performance of sub-
sequent MDA rounds. With the enhanced approach to MDA and additional measures applied
with the use of IDA, we should expect to see some of these never treated individuals reached
for the first time in 2019. In addition, follow-up studies can assess if there is improved accept-
ability (or not) to the use of IDA in these regions, following the 2019 MDA.
Finally, this paper shows the value of performing applied research to assess social behavior
and factors related to coverage to inform subsequent MDA rounds, particularly before the
national introduction of IDA. This study was incorporated within a larger sentinel site study
and so provided an opportunity to include these questions with minimal additional budget.
Similar opportunities should be explored whereby a short assessment of history of treatment,
acceptability and perception across key messages can be added to parasitological mapping and
assessments as well as to coverage surveys. This will not only be more cost-efficient but will
allow a more detailed understanding of community response to MDA so that future rounds
can be reoriented, as needed. The Guyanese program applied the recommendations from this
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study in both rounds of IDA in 2019 and 2021. Because the data were collected only a few
months prior to the 2019 MDA, there was limited time to apply all recommendations for that
round. In 2021, there was more time to plan and a more regional approach to social mobiliza-
tion was promoted.
Limitations of study
Perhaps the most important limitation of the study was the missing data for Region X for the
key outcome of interest, acceptability. After repeated attempts to understand why this
occurred, the research team decided to move forward with the analysis and assume that there
was no chance of data recovery. To account for these missing data, the team undertook a sensi-
tivity analysis to ascertain the impact on the final acceptability model. In that model, the team
was assured of the robustness of the final model which included a smaller sample from Region
X, as compared to the other three regions.
Studies of this nature benefit from the added qualitative component to validate the results
that arise from the survey results. In this case, timing and budgetary constraints prohibited the
research team from carrying out concurrent qualitative research to understand those individ-
ual factors underpinning MDA coverage. The study team would recommend additional
research to build on the findings of this study to further probe into the reasons why people
refuse to take treatment over multiple rounds and into the rationale behind the “don’t know”
responses, particularly to understand why there are differences across sex.
Other important limitations to the study include the over-representation of women in the
study sample and the targeted nature of the Filarial Re-Mapping Survey. Given the time of the
day when the data were collected, men are often outside of the home. This phenomenon has
been seen in similar studies [44]. Compliance and acceptability have been shown to be highly
contextual, dependent on multiple personal, social, community and health system factors. As
such, we are unable to comment on whether this over-representation of women skews the
study more positively or negatively. Additionally, the acceptability survey was based on a sub-
sample of a large-scale effort to re-map and define implementation units where MDA rollout
may pose particular challenges. These site characteristics (high transmission settings, cultural,
geographic, or economic barriers to MDA access, etc.) contribute to concerns about the gener-
alizability of the sample, though the aforementioned lack of a qualitative component make it
difficult to assess how this may bias the results.
In a similar study we did not see an association between acceptability and infection status
[23]. Regardless, inclusion of this data and that of related protective behaviors such as bednet
use or window screens would have been useful to include in the analysis if the data had been
available.
Conclusion
The study showed sufficient levels of acceptability of previous MDA rounds in four regions in Guy-
ana. Region was the most important indicator for compliance and acceptability suggesting that tai-
lored regionally specific responses may be necessary to ensure effective coverage with MDA. The
results from the study were used to inform the next two rounds of MDA (2019 and 2021) and pro-
vided a baseline level of acceptability for MDA with DA against which IDA can be measured.
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